Search results
Results From The WOW.Com Content Network
Elevations in target cells are the result of a shift in the exchange equilibrium between the red blood cells and the cholesterol. Also, the surface membrane to volume ratio is increased. Target cells are more resistant to osmotic lysis, which is mostly seen in dogs. Hypochromic cells in iron deficiency anemias also can show a target appearance.
Another form of targeted therapy involves the use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body. Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells.
Antibody-dependent cellular cytotoxicity. Antibody-dependent cellular cytotoxicity (ADCC), also referred to as antibody-dependent cell-mediated cytotoxicity, is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system kills a target cell, whose membrane-surface antigens have been bound by specific antibodies. [1]
The resulting complex – amino acid, linker and cytotoxic agent – is considered to be the active drug. In contrast, cleavable linkers are detached by enzymes in the cancer cell. The cytotoxic payload can then escape from the targeted cell and, in a process called "bystander killing", attack neighboring cells. [51]
Macrocytic anemia is a class of anemia characterized by the presence of predominantly larger-than-normal red blood cells (RBC, also known as erythrocytes) accompanied by low numbers of RBC and often also with insufficient hemoglobin content per cell. Macrocytic anemia occurs when – despite the larger cell size – such factors result in ...
Cellular immunity protects the body through: T-cell mediated immunity or T-cell immunity: activating antigen-specific cytotoxic T cells that are able to induce apoptosis in body cells displaying epitopes of foreign antigen on their surface, such as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens;
The term "biological target" is frequently used in pharmaceutical research to describe the native protein in the body whose activity is modified by a drug resulting in a specific effect, which may be a desirable therapeutic effect or an unwanted adverse effect. In this context, the biological target is often referred to as a drug target.
Complement-dependent cytotoxicity (CDC) is an effector function of IgG and IgM antibodies.When they are bound to surface antigen on target cell (e.g. bacterial or viral infected cell), the classical complement pathway is triggered by bonding protein C1q to these antibodies, resulting in formation of a membrane attack complex (MAC) and target cell lysis.